These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25594041)

  • 21. Mutant p53 partners in crime.
    Kim MP; Lozano G
    Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
    Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
    Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
    Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.
    Ji Q; Hao X; Meng Y; Zhang M; Desano J; Fan D; Xu L
    BMC Cancer; 2008 Sep; 8():266. PubMed ID: 18803879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.
    Alexandrova EM; Marchenko ND
    Front Endocrinol (Lausanne); 2015; 6():53. PubMed ID: 25954247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting mutant p53 in cancer: the latest insights.
    Di Agostino S; Fontemaggi G; Strano S; Blandino G; D'Orazi G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):290. PubMed ID: 31277687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer.
    Madrigal T; Hernández-Monge J; Herrera LA; González-De la Rosa CH; Domínguez-Gómez G; Candelaria M; Luna-Maldonado F; Calderón González KG; Díaz-Chávez J
    Front Cell Dev Biol; 2021; 9():695723. PubMed ID: 34957087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.
    Walerych D; Pruszko M; Zyla L; Wezyk M; Gaweda-Walerych K; Zylicz A
    Oncotarget; 2018 Aug; 9(62):32063-32080. PubMed ID: 30174797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant p53 in cancer therapy-the barrier or the path.
    Zhou X; Hao Q; Lu H
    J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
    Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic Intra-p53 Family Member Interactions in Human Cancers.
    Ferraiuolo M; Di Agostino S; Blandino G; Strano S
    Front Oncol; 2016; 6():77. PubMed ID: 27066457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic targets of
    Tanaka T; Watanabe M; Yamashita K
    Oncotarget; 2018 Mar; 9(22):16234-16247. PubMed ID: 29662640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.